Skip to content

Study · Non-randomized trial · n = 10 · 2003

2 results

Changes in appetite and body weight in response to long-term oral administration of the ghrelin agonist GHRP-2 in growth hormone deficient children.

Mericq V, Cassorla F, Bowers CY, Avila A, Gonen B, Merriam GR

Journal of pediatric endocrinology & metabolism : JPEM1 Sept 2003Cited by 17 (Europe PMC)

PMID14513874 (opens in a new tab)DOI10.1515/jpem.2003.16.7.981 (opens in a new tab)PepBankPUB-14513874
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In prepubertal children with GH deficiency, oral GHRP‑2 was followed by a significant increase in appetite in seven of ten patients during the first 6 months.

    In plain wordsIn children with growth hormone deficiency, seven of ten reported a clear rise in appetite during the first 6 months of oral GHRP‑2.

    Peptide
    GHRP-2
    Outcome
    IncreaseAppetite increase during first 6 months
    Study

    n = 10

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    900 microg/kg b.i.d. · oral · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Seven out of ten patients reported a significant increase in appetite during the first 6 months of the study.
    2 context sentences
    Summary · context
    Ten prepubertal children with GH deficiency (growth velocity < or = 4 cm/year in association with a GH response to two provocative stimuli < 10 ng/ml) were included in the study.
    Summary · context
    GHRP-2 was administered orally at a dose of 900 microg/kg b.i.d. for 12 months.
  2. 02HumanNon-randomized trialEfficacy outcome

    In prepubertal children with GH deficiency, BMI SDS tended to increase during oral GHRP‑2 treatment, but the increase was not statistically significant.

    In plain wordsIn children with growth hormone deficiency, body mass index showed a small rise during oral GHRP‑2 that was not statistically significant.

    Peptide
    GHRP-2
    Outcome
    No significant changeBMI SDS change over 12 months
    Study

    n = 10

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    900 microg/kg b.i.d. · oral · 12 monthsAs given in this study (human).

    Measurements

    BMI SDS
    0.21 SDS
    baseline
    BMI SDS
    0.25 SDS
    end of study

    Source sentences

    Summary
    There was a tendency for the BMI SDS to increase during the study, but this increase did not reach statistical significance (0.21 +/- 1.5 vs 0.25 +/- 1.5 SDS).
    2 context sentences
    Summary · context
    Ten prepubertal children with GH deficiency (growth velocity < or = 4 cm/year in association with a GH response to two provocative stimuli < 10 ng/ml) were included in the study.
    Summary · context
    GHRP-2 was administered orally at a dose of 900 microg/kg b.i.d. for 12 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.